462 F.Supp.3d 557
E.D. Pa.2020Background
- Decedent Joanne Polt took generic amiodarone (prescribed off‑label for atrial fibrillation) for ~5 years and died after developing pulmonary fibrosis, a known amiodarone risk.
- Sandoz, a generic manufacturer, used the same physician warning label as the brand and complied with the FDA "sameness" requirement; FDA also requires medication guides be supplied to pharmacies for patient distribution.
- The Polts sued for wrongful death alleging (1) failure to warn physicians, (2) inadequate warnings to physicians, and (3) failure to provide medication guides to the patient (negligence per se and failure‑to‑warn theories).
- On summary judgment the court found: claims alleging inadequate physician warnings and failure to provide a medication guide are impliedly preempted; the claim that no warning was given to physicians (not preempted) failed on the facts because physicians were aware of pulmonary toxicity.
- The court applied Pennsylvania’s learned intermediary doctrine (manufacturer’s duty is to warn prescribing physicians, not patients) and refused to create an FDA‑regulation‑based exception under these facts.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether a manufacturer owes a state‑law duty to warn patients directly (medication guide) | Polt: FDA medication‑guide rules impose/reflect a state‑law duty; negligence per se can enforce FDCA duties | Sandoz: Pennsylvania follows learned intermediary; no duty to directly warn patients; federal law preempts parallel state claims | Court: No state duty to warn patients directly; learned intermediary applies; medication‑guide claim preempted |
| Whether claims based on inadequate physician warnings are preempted for generics | Polt: Label inadequate, so state failure‑to‑warn claim valid | Sandoz: Generic sameness rule makes unilateral label changes impossible; such claims are impossibility‑preempted | Court: Inadequate‑label claims preempted under Mensing (impossibility) |
| Whether a claim that no warning was given to physicians survives | Polt: Evidence (Dr. Cox testimony) creates factual dispute about what physicians knew | Sandoz: Physicians knew risk of pulmonary toxicity; evidence shows warnings reached physicians | Court: Claim not preempted but fails on the merits—no genuine dispute physicians were aware of the risk |
| Whether to adopt an FDA‑regulations exception to the learned intermediary doctrine | Polt: Court should create an exception because FDA requires patient labeling | Sandoz: Exception would expand tort liability and is unsupported by Pennsylvania precedent; FDA regs alone don’t displace the doctrine | Court: Declines to craft new exception; even if adopted, it wouldn’t apply because it’s not foreseeable physicians would be bypassed here |
Key Cases Cited
- Incollingo v. Ewing, 282 A.2d 206 (Pa. 1971) (establishes learned intermediary rule: duty to warn physicians, not patients)
- Coyle v. Richardson‑Merrell, Inc., 584 A.2d 1383 (Pa. 1991) (physician as gatekeeper; manufacturer’s duty is to inform prescribing doctor)
- PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011) (generic manufacturer cannot unilaterally change label; adequacy claims for generics may be preempted by impossibility)
- Wyeth v. Levine, 555 U.S. 555 (2009) (state tort claims generally coexist with FDCA unless they obstruct federal objectives)
- Mutual Pharm. Co. v. Bartlett, 570 U.S. 472 (2013) (impossibility preemption where compliance with state and federal law is impossible)
- Buckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341 (2001) (state claims that exist solely by virtue of the FDCA can conflict with federal objectives)
- Mazur v. Merck & Co., 964 F.2d 1348 (3d Cir. 1992) (mass‑immunization context supports exception to learned intermediary when individualized physician judgment is absent)
- Taurino v. Ellen, 579 A.2d 925 (Pa. Super. Ct. 1990) (refuses contraceptive exception where manufacturer had no reason to foresee bypassing physicians)
- Colacicco v. Apotex, Inc., 521 F.3d 253 (3d Cir. 2008) (noting strict application of learned intermediary doctrine in Pennsylvania)